<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32152380</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis.</ArticleTitle><Pagination><StartPage>4308</StartPage><MedlinePgn>4308</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4308</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-61246-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease for which the pathophysiological mechanisms of motor neuron loss are not precisely clarified. Environmental and epigenetic mechanisms such as microRNAs (miRNAs) could have a role in disease progression. We studied the expression pattern of miRNAs in ALS serum from 60 patients and 29 healthy controls. We also analyzed how deregulated miRNAs found in serum affected cellular pathways such as apoptosis, autophagy and mitochondrial physiology in SH-SY5Y cells. We found that miR-335-5p was downregulated in ALS serum. SH-SY5Y cells were transfected with a specific inhibitor of miR-335-5p and showed abnormal mitochondrial morphology, with an increment of reactive species of oxygen and superoxide dismutase activity. Pro-apoptotic caspases-3 and 7 also showed an increased activity in transfected cells. The downregulation of miR-335-5p, which has an effect on mitophagy, autophagy and apoptosis in SH-SY5Y neuronal cells could have a role in the motor neuron loss observed in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Luna</LastName><ForeName>Noemi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory - Biomedical Research Institute SantPau, Universitat Aut&#xf3;noma de Barcelona, Barcelona, Spain. nluna@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain. nluna@santpau.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turon-Sans</LastName><ForeName>Joana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes-Vicente</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasco-Rozas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory - Biomedical Research Institute SantPau, Universitat Aut&#xf3;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ill&#xe1;n-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarim&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory - Biomedical Research Institute SantPau, Universitat Aut&#xf3;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illa</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory - Biomedical Research Institute SantPau, Universitat Aut&#xf3;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Garc&#xed;a</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Laboratory - Biomedical Research Institute SantPau, Universitat Aut&#xf3;noma de Barcelona, Barcelona, Spain. rrojas@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. rrojas@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain. rrojas@santpau.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556347">MIRN335 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32152380</ArticleId><ArticleId IdType="pmc">PMC7062873</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-61246-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-61246-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown, R. H. &amp; Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N Engl J Med. 377(2), 162&#x2013;72 (2017 Jul 13).</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser, F. et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 65(5), 636&#x2013;41 (2008 May).</Citation><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, C. M., Grace, G. M., Munoz, D. G., He, B. P. &amp; Strong, M. J. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multisystem disorder. Neurology. 57(4), 651&#x2013;7 (2001 Aug 28).</Citation><ArticleIdList><ArticleId IdType="pubmed">11524474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson, L. G. &amp; Bodin, L. Amyotrophic Lateral Sclerosis and Occupational Exposures: A Systematic Literature Review and Meta-Analyses. Int J Environ Res Public Health. 15(11) (2018 Oct 26).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6265680</ArticleId><ArticleId IdType="pubmed">30373166</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson, B., Gendron, T. F. &amp; Staff, N. P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 93(11), 1617&#x2013;28 (2018 Nov).</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi, A. et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 124(3), 339&#x2013;52 (2012 Sep).</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front. Genet. 2018;9:712. doi: 10.3389/fgene.2018.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis, E. et al. The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. J Mol Neurosci. 66(9), 617&#x2013;28 (2018 Nov 10).</Citation></Reference><Reference><Citation>Chen, P. Y. &amp; Meister, G. microRNA-guided posttranscriptional gene regulation. Biol Chem. 386(12), 1205&#x2013;18 (2005 Dec).</Citation><ArticleIdList><ArticleId IdType="pubmed">16336116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebert, L. F. R. &amp; MacRae, I. J. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 20(1), 21&#x2013;37 (2018 Aug 14).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546304</ArticleId><ArticleId IdType="pubmed">30108335</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J. &amp; Shaw, P. J. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci. 7, 178 (2013 Oct 10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794211</ArticleId><ArticleId IdType="pubmed">24133413</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteller, M. Non-coding RNAs in human disease. Nat Rev Genet. 12(12), 861&#x2013;74 (2011 Nov 18).</Citation><ArticleIdList><ArticleId IdType="pubmed">22094949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kye MJ, Goncalves Ido C. The role of miRNA in motor neuron disease. Front. Cell Neurosci. 2014;8:15. doi: 10.3389/fncel.2014.00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00015</ArticleId><ArticleId IdType="pmc">PMC3906579</ArticleId><ArticleId IdType="pubmed">24523674</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Parisi C. MicroRNAs: newcomers into the ALS picture. CNS Neurol. Disord. Drug. Targets. 2015;14(2):194&#x2013;207. doi: 10.2174/1871527314666150116125506.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150116125506</ArticleId><ArticleId IdType="pubmed">25613506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi, S. et al. PINK1-associated Parkinson&#x2019;s disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell. 33(5), 627&#x2013;38 (2009 Mar 13).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724101</ArticleId><ArticleId IdType="pubmed">19285945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SM, et al. Intermittent hypoxia can aggravate motor neuronal loss and cognitive dysfunction in ALS mice. PLoS One. 2013;8(11):e81808. doi: 10.1371/journal.pone.0081808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0081808</ArticleId><ArticleId IdType="pmc">PMC3841127</ArticleId><ArticleId IdType="pubmed">24303073</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi, G. &amp; Xu, Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 5(2), 77&#x2013;87 (2005 Apr).</Citation><ArticleIdList><ArticleId IdType="pubmed">16050975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer, G. &amp; Reed, J. C. Mitochondrial control of cell death. Nat Med. 6(5), 513&#x2013;9 (2000 May).</Citation><ArticleIdList><ArticleId IdType="pubmed">10802706</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal, K. &amp; Tiwari, A. K. Mitochondrial dynamics, a key executioner in neurodegenerative diseases. Mitochondrion. 47, 151-73 (2018 Nov 5).</Citation><ArticleIdList><ArticleId IdType="pubmed">30408594</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino, M. &amp; Carri, M. T. Mitochondrial dysfunction in ALS. Prog Neurobiol. 97(2), 54&#x2013;66 (2012 May).</Citation><ArticleIdList><ArticleId IdType="pubmed">21827820</ArticleId></ArticleIdList></Reference><Reference><Citation>Federico, A. et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 322(1&#x2013;2), 254&#x2013;62 (2012 Nov 15).</Citation><ArticleIdList><ArticleId IdType="pubmed">22669122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorov, D. B., Juhaszova, M. &amp; Sollott, S. J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 94(3), 909&#x2013;50 (2014 Jul).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4101632</ArticleId><ArticleId IdType="pubmed">24987008</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton, G. J. &amp; Jauniaux, E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 25(3), 287&#x2013;99 (2011 Jun).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101336</ArticleId><ArticleId IdType="pubmed">21130690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. Redox Biol. 2014;2:702&#x2013;14. doi: 10.1016/j.redox.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2014.05.006</ArticleId><ArticleId IdType="pmc">PMC4060303</ArticleId><ArticleId IdType="pubmed">24944913</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson, J. &amp; Duchen, M. R. Mitochondrial oxidative stress and cell death in astrocytes&#x2013;requirement for stored Ca2+ and sustained opening of the permeability transition pore. J Cell Sci. 115(Pt 6), 1175&#x2013;88 (2002 Mar 15).</Citation><ArticleIdList><ArticleId IdType="pubmed">11884517</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, J. P., Brown, R. H. Jr. &amp; Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature. 539(7628), 197&#x2013;206 (2016 Nov 10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure, T., Kawano, H., Abe, Y. &amp; Miyawaki, A. Fluorescence imaging using a fluorescent protein with a large Stokes shift. Methods. 45(3), 223&#x2013;6 (2008 Jul).</Citation><ArticleIdList><ArticleId IdType="pubmed">18586106</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzeiy H, et al. Visualization and Analysis of miRNAs Implicated in Amyotrophic Lateral Sclerosis Within Gene Regulatory Pathways. Stud. Health Technol. Inform. 2018;253:183&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30147069</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchetti, A. et al. A Perturbed MicroRNA Expression Pattern Characterizes Embryonic Neural Stem Cells Derived from a Severe Mouse Model of Spinal Muscular Atrophy (SMA). Int J Mol Sci. 16(8), 18312&#x2013;27 (2015 Aug 6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581247</ArticleId><ArticleId IdType="pubmed">26258776</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdocca, M. et al. SMA Human iPSC-Derived Motor Neurons Show Perturbed Differentiation and Reduced miR-335-5p Expression. Int J Mol Sci. 17(8), e1231 (2016 Jul 30).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5000629</ArticleId><ArticleId IdType="pubmed">27483257</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitano, F. et al. MicroRNA-335-5p modulates spatial memory and hippocampal synaptic plasticity. Neurobiol Learn Mem. 139, 63&#x2013;8 (2017 Mar).</Citation><ArticleIdList><ArticleId IdType="pubmed">28039088</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller, R. et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 55:123&#x2013;31 (2017 Jul).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja, R. et al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 58(2), 261&#x2013;9 (2018 Aug).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>Golpich, M. et al. Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. CNS Neurosci Ther. 23(1), 5&#x2013;22 (2017 Jan).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492703</ArticleId><ArticleId IdType="pubmed">27873462</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuragi, Y., Ichimura, Y. &amp; Komatsu, M. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J. 282(24), 4672&#x2013;8 (2015 Dec).</Citation><ArticleIdList><ArticleId IdType="pubmed">26432171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivankovic, D., Chau, K. Y., Schapira, A. H. &amp; Gegg, M. E. Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J Neurochem. 136(2), 388&#x2013;402 (2016 Jan).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4949652</ArticleId><ArticleId IdType="pubmed">26509433</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter, B. et al. Oxidative stress in skeletal muscle stimulates early expression of Rad in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 48(7), 915&#x2013;23 (2010 Apr 1).</Citation><ArticleIdList><ArticleId IdType="pubmed">20079427</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic, N. et al. Early activation of antioxidant mechanisms in muscle of mutant Cu/Zn-superoxide dismutase-linked amyotrophic lateral sclerosis mice. Ann N Y Acad Sci. 1010, 552&#x2013;6 (2003 Dec).</Citation><ArticleIdList><ArticleId IdType="pubmed">15033789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoye, A. T., Davoren, J. E., Wipf, P., Fink, M. P. &amp; Kagan, V. E. Targeting mitochondria. Acc Chem Res. 41(1), 87&#x2013;97 (2008 Jan).</Citation><ArticleIdList><ArticleId IdType="pubmed">18193822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi, M. &amp; Kanneganti, T. D. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 42(1), 21&#x2013;4 (2010 Jan).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787741</ArticleId><ArticleId IdType="pubmed">19782763</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front. Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B. R., Miller, R. G., Swash, M. &amp; Munsat, T. L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1(5), 293&#x2013;9 (2000 Dec).</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala, I. et al. CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 91(17), e1619&#x2013;e28 (2018 Oct 23).</Citation><ArticleIdList><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 134(Pt 9), 2456&#x2013;77 (2011 Sep).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco-Rozas, A. et al. Identification of serum microRNAs as potential biomarkers in Pompe disease. Ann Clin Transl Neurol. 6(7), 1214&#x2013;24 (2019 Jul).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649638</ArticleId><ArticleId IdType="pubmed">31353854</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luna, N et al. Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. J Neuropathol Exp Neurol. 77(10), 964&#x2013;72 (2018 Oct 1).</Citation><ArticleIdList><ArticleId IdType="pubmed">30184235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>